NCT03156621 - Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 3, 2017

Primary Completion Date

September 27, 2019

Study Completion Date

February 13, 2020

Conditions

Homozygous Familial Hypercholesterolemia

Interventions

DRUG

Alirocumab

Alirocumab SC Q2W

DRUG

Placebo

Matching placebo SC Q2W

Trial Locations (28)

2000

Regeneron Research Site, Parktown

6020

Regeneron Research Site, Innsbruck

7925

Regeneron Research Site, Cape Town

10029

Regeneron Research Site, New York

11217

Regeneron Study Site, Taipei

12200

Regeneron Research Site, Berlin

13285

Regeneron Research Site, Marseille

17674

Regeneron Research Site, Athens

33434

Regeneron Research Site, Boca Raton

35040

Regeneron Research Site, Izmir

45227

Regeneron Research Site, Cincinnati

45500

Regeneron Research Site, Ioannina

61039

Regeneron Research Site, Kharkiv

61176

Regeneron Research Site, Kharkiv

75651

Regeneron Research Site, Paris

76005

Regeneron Research Site, Ivano-Frankivsk

78226

Regeneron Study Site, Dallas

80131

Regeneron Research Site, Napoli

G7H 7K9

Regeneron Research Site, Chicoutimi

GIV 4W2

Regeneron Research Site, Québec

128 08

Regeneron Research Site, Prague

00161

Regeneron Research Site, Roma

662-0918

Regeneron Research Site, Nishinomiya

920-8641

Regeneron Research Site, Kanazawa

565-8565

Regeneron Research Site, Suita

06500

Regeneron Research Site, Beşevler

02166

Regeneron Research Site, Kyiv

03680

Regeneron Research Site, Kyiv